Pantothenate kinase-associated neurodegeneration (Pkan)

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Significant gains in our understanding of the biochemical defects in PKAN have shifted the therapeutic focus from palliative care to rational interventions. Novel therapies aimed at correcting specific perturbations in cellular metabolism hold great promise and are currently under investigation. Treatment of this rare neurode-generative disorder is likely to change significantly over the next decade.

Original languageEnglish (US)
Title of host publicationTreatment of Pediatric Neurologic Disorders
PublisherCRC Press
Pages355-359
Number of pages5
ISBN (Electronic)9780849340888
ISBN (Print)0824726936, 9780824726935
StatePublished - Jan 1 2005

Fingerprint

Pantothenate Kinase-Associated Neurodegeneration
Palliative Care
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hayflick, S. (2005). Pantothenate kinase-associated neurodegeneration (Pkan). In Treatment of Pediatric Neurologic Disorders (pp. 355-359). CRC Press.

Pantothenate kinase-associated neurodegeneration (Pkan). / Hayflick, Susan.

Treatment of Pediatric Neurologic Disorders. CRC Press, 2005. p. 355-359.

Research output: Chapter in Book/Report/Conference proceedingChapter

Hayflick, S 2005, Pantothenate kinase-associated neurodegeneration (Pkan). in Treatment of Pediatric Neurologic Disorders. CRC Press, pp. 355-359.
Hayflick S. Pantothenate kinase-associated neurodegeneration (Pkan). In Treatment of Pediatric Neurologic Disorders. CRC Press. 2005. p. 355-359
Hayflick, Susan. / Pantothenate kinase-associated neurodegeneration (Pkan). Treatment of Pediatric Neurologic Disorders. CRC Press, 2005. pp. 355-359
@inbook{7c24179b46b64392b90cedb7585191c5,
title = "Pantothenate kinase-associated neurodegeneration (Pkan)",
abstract = "Significant gains in our understanding of the biochemical defects in PKAN have shifted the therapeutic focus from palliative care to rational interventions. Novel therapies aimed at correcting specific perturbations in cellular metabolism hold great promise and are currently under investigation. Treatment of this rare neurode-generative disorder is likely to change significantly over the next decade.",
author = "Susan Hayflick",
year = "2005",
month = "1",
day = "1",
language = "English (US)",
isbn = "0824726936",
pages = "355--359",
booktitle = "Treatment of Pediatric Neurologic Disorders",
publisher = "CRC Press",

}

TY - CHAP

T1 - Pantothenate kinase-associated neurodegeneration (Pkan)

AU - Hayflick, Susan

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Significant gains in our understanding of the biochemical defects in PKAN have shifted the therapeutic focus from palliative care to rational interventions. Novel therapies aimed at correcting specific perturbations in cellular metabolism hold great promise and are currently under investigation. Treatment of this rare neurode-generative disorder is likely to change significantly over the next decade.

AB - Significant gains in our understanding of the biochemical defects in PKAN have shifted the therapeutic focus from palliative care to rational interventions. Novel therapies aimed at correcting specific perturbations in cellular metabolism hold great promise and are currently under investigation. Treatment of this rare neurode-generative disorder is likely to change significantly over the next decade.

UR - http://www.scopus.com/inward/record.url?scp=85056431418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056431418&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85056431418

SN - 0824726936

SN - 9780824726935

SP - 355

EP - 359

BT - Treatment of Pediatric Neurologic Disorders

PB - CRC Press

ER -